Vanessa Carle sold $10k of LEXX
Secretary at Lexaria Bioscience Corp.. 2,567 shares at an average of $4.00, traded Jul 31, 2024, filed Aug 1, 2024.
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001855763-24-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | SOpen-market sale common shares | -2,567 | $4.00 | $10k | 0 | Aug 1, 2024 |
Related signals
Other insiders at Lexaria Bioscience Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Lexaria Bioscience Corp. | Christopher Bunka Chief Executive Officer | $25k 27,500 shares | +11% | |
| 64Notable | Lexaria Bioscience Corp. | Richard Christopher Chief Executive Officer | $14k 15,000 shares | +30% | |
| 56Moderate | Lexaria Bioscience Corp. | Vanessa Carle Secretary | $683 750 shares | - | |
| 61Notable | Lexaria Bioscience Corp. | John Martin Docherty President & CSO | $4,989 5,376 shares | - | |
| 54Moderate | Lexaria Bioscience Corp. | William Edward McKechnie director | $4,532 5,000 shares | +38% | |
| 43Moderate | LEXXbuy Lexaria Bioscience Corp. | Richard Christopher Chief Executive Officer | $118k 50,000 shares | - | |
| 33Weak | LEXXbuy Lexaria Bioscience Corp. | Catherine C. Turkel director | $5,008 1,600 shares | +107% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.